白芍总苷胶囊对eae大鼠防治作用的分析-analysis of preventive and therapeutic effects of total glucosides of paeony capsule on eae rats.docxVIP

optical microscope to observe the pathological changes in the enzyme-linked immunosorbent assay (by enzyme-linked immunosorbent assay ELISA) assay rats in each group peak incidence of peripheral blood mononuclear cells (peripheral blood mononuclear cell, PBMC) secretion of INF-γ, IL-4 levels and brain tissue cytokines IL-2, TNF-alpha content, determined by flow cytometry rats in each group the peak incidence of peripheral blood lymphocytes subsets. SPSS17.0 software package for statistical analysis. Results: 1. Rats in each group of clinical manifestations observed: ① adjuvant incidence in rats. ② EAE group compared with the low dose group can reduce the clinical symptoms (p 0.05), reduce morbidity, prolong the incubation period, shorten the advanced stage (p 0.05), the difference was statistically significant; middle and high dose TGP group than in the EAE group can reduce morbidity, prolong the incubation period, shortening the progress of and reduce the clinical symptoms (p 0.05) difference was statistically significant. High, medium and low-dose TGP group group it with the difference to reduce morbidity and prolong the incubation period, shorten the period of progress, and to reduce the clinical symptoms in a dose dependent manner (p 0.05) difference was statistically significant. Two. Rats in each group of CNS pathology observed: ① HE staining adjuvant rats periventricular white matter inflammatory lesions. ② different dose TGP group the number of inflammatory lesions in EAE group reduced. Adjuvant brain tissue infiltration of inflammatory cells, the more typical demyelinating lesions of EAE group, only a few of the different doses of FTY720 group occasionally demyelinating lesions. Each group of rat peripheral blood of INF-γ, IL-4: To compare the adjuvant group, EAE INF-γ high IL-4 (p 0.05); medium and small-TGP group EAE group of INF-γ relative smaller doses of IL-4 is relatively low (p 0.05), medium dose group